Walvax

Kunming, China Founded: 2001 • Age: 25 yrs
Chinese vaccine manufacturer specializing in vaccines for meningitis and influenza
Request Access

About Walvax

Walvax is a company based in Kunming (China) founded in 2001.. The company has 1,930 employees as of December 31, 2024. Walvax operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.

  • Headquarter Kunming, China
  • Employees 1930 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Walvax Biotechnology Co., Ltd. Class A
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $383.59 M (USD)
    -31.34
    as on Dec 31, 2024
  • Net Profit
    $19.48 M (USD)
    -66.1
    as on Dec 31, 2024
  • EBITDA
    $66.9 M (USD)
    -50.53
    as on Dec 31, 2024
  • Latest Funding Round
    $72.8 M (USD), Post-IPO

    Aug 10, 2014

  • Investors
  • Employee Count
    1930

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Walvax

Walvax is a publicly listed company on the SZSE with ticker symbol 300142 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: SZSE · Ticker: 300142 . Sector: Health technology · China

Funding Insights of Walvax

  • Total Funding
  • Total Rounds 1
  • Last Round Post-IPO — $72.8M
  • First Round

    (10 Aug 2014)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2014 Amount Post-IPO - Walvax Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Walvax

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Walvax

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Walvax Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Walvax

Walvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
domain founded_year HQ Location
Vaccines for infectious diseases are developed using cell-free protein synthesis.
domain founded_year HQ Location
Developer of immunotherapies for the treatment of infectious diseases and cancer
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Vaccines and therapeutics for multiple diseases are developed and marketed.
domain founded_year HQ Location
Gene therapy platform is developed for chronic disease treatments.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Walvax

Frequently Asked Questions about Walvax

When was Walvax founded?

Walvax was founded in 2001 and raised its 1st funding round 13 years after it was founded.

Where is Walvax located?

Walvax is headquartered in Kunming, China. It is registered at Kunming, Yunnan, China.

How many employees does Walvax have?

As of Dec 31, 2024, the latest employee count at Walvax is 1,930.

What is the annual revenue of Walvax?

Annual revenue of Walvax is $383.59M as on Dec 31, 2024.

What does Walvax do?

Walvax was founded in 2001 in Kunming, China, as a vaccine manufacturer focused on the biopharmaceutical sector. Specialization is placed on developing and producing vaccines against meningitis and influenza. An in-house RD center is operated to support innovation. The company was listed publicly in November 2010, enabling expanded operations within the Chinese market and beyond.

Who are the top competitors of Walvax?

Walvax's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.

Is Walvax publicly traded?

Yes, Walvax is publicly traded on SZSE under the ticker symbol 300142.

What is Walvax's ticker symbol?

The ticker symbol of Walvax is 300142 on SZSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available